<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04031040</url>
  </required_header>
  <id_info>
    <org_study_id>CL-GEN-002068</org_study_id>
    <nct_id>NCT04031040</nct_id>
  </id_info>
  <brief_title>A Post-market Clinical Follow up of the Genio™ System for the Treatment of Obstructive Sleep Apnea in Adults</brief_title>
  <acronym>EliSA</acronym>
  <official_title>A Post-market Clinical Follow up of the Genio™ System for the Treatment of Obstructive Sleep Apnea in Adults.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nyxoah S.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nyxoah S.A.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to confirm the safety and clinical effectiveness of
      the Genio™ system, used according to its instructions for use, in moderate to severe
      Obstructive Sleep Apnea (OSA) adult patients over a period of 3 years post-surgery.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2019</start_date>
  <completion_date type="Anticipated">October 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of all reported Serious Adverse Events (SAEs) and all procedure- or device-related Adverse Events (AEs)</measure>
    <time_frame>12 months post-surgery</time_frame>
    <description>Incidence of all reported Serious Adverse Events (SAEs) and all procedure- or device-related Adverse Events (AEs) reported during the study</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Apnea-Hypopnea Index from baseline</measure>
    <time_frame>12 months post-surgery</time_frame>
    <description>Change in Apnea-Hypopnea Index (AHI) from baseline as measured by sleep lab</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in the quality of life measured by the Functional Outcomes of Sleep Questionnaire</measure>
    <time_frame>12 months post-surgery</time_frame>
    <description>Change in the quality of life measured by the Functional Outcomes of Sleep Questionnaire (FOSQ)</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Obstructive Sleep Apnea</condition>
  <arm_group>
    <arm_group_label>Genio(TM) system therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Following activation of the Genio™ system at 8 weeks post-surgery, patients will be followed at 12 weeks, 6 months, 10 months, 12 months and then every year for a total period of 3 years after surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Genio(TM) system therapy</intervention_name>
    <description>Hypoglossal nerve stimulation system</description>
    <arm_group_label>Genio(TM) system therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body Mass Index (BMI) &lt; 35 kg/m2

          -  AHI between 15 to 65 events/hour documented by a PSG during the screening phase.

          -  Has either not tolerated, has failed or refused Positive Airway Pressure (PAP) or
             Mandibular Advancement Device (MAD) treatments.

        Exclusion Criteria:

          -  Night shift worker

          -  Significant comorbidities that contraindicates surgery

          -  Life expectancy &lt; 12 months

          -  Participation in another clinical study (excluding registries) during the study period
             (3 years).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joachim T. Maurer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Klinik für HNO-Heilkunde, Mannheim</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Guillaume Raux</last_name>
    <phone>+32 10 22 48 68</phone>
    <email>guillaume.raux@nyxoah.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Klinik für HNO-Heilkunde, Kopf- und Halschirurgie, Schlafmedizinisches Zentrum</name>
      <address>
        <city>Mannheim</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+49 151 6740 9957</phone>
      <email>mbx-hno-schlaf@umm.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>July 18, 2019</study_first_submitted>
  <study_first_submitted_qc>July 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 24, 2019</study_first_posted>
  <last_update_submitted>September 16, 2019</last_update_submitted>
  <last_update_submitted_qc>September 16, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Apnea</mesh_term>
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Sleep Apnea, Obstructive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

